Hospital
UPMC Greene
UPMC Greene was paid $2.67M by Medicaid between Feb 2020 and Oct 2024, across 70 billing codes. Its largest line is 99285, emergency room visit (most serious) — 37% of everything it billed.
33Billing provider infoUPMC GREENE
WAYNESBURG, PA 15370
WAYNESBURG, PA 15370
33aNPI1225417421assigned 05/21/2015
33bProvider typeGeneral Acute Care Hospital
28Total paid$2.67M
24GClaims43,902
24DCodes billed70
24AFirst – last monthFeb 2020 – Oct 2024
Compared with peers
Next to other General Acute Care Hospital providers in Pennsylvania
Rank by total paid#81 of 154
Median peer was paid$2.82M
This provider vs. median0.9×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2020 | 3,368 | $105K | |
| 2021 | 15,425 | $518K | |
| 2022 | 10,009 | $761K | |
| 2023 | 9,909 | $778K | |
| 2024incomplete | 5,191 | $509K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 37% | 4,096 | 3,993 | $993K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 29% | 6,415 | 6,235 | $762K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 17% | 2,720 | 2,657 | $457K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 2.7% | 1,793 | 1,749 | $72K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 2.4% | 1,054 | 1,021 | $64K |
| G0378 | Hospital observation service, per hour | 1.0% | 51 | 50 | $28K |
| 80306 | <1% | 1,334 | 1,242 | $23K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 108 | 108 | $21K |
| 80053 | Comprehensive metabolic panel | <1% | 2,921 | 2,771 | $20K |
| 71045 | Radiologic examination, chest; single view | <1% | 809 | 792 | $19K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 2,289 | 2,234 | $18K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 5,252 | 4,932 | $17K |
58 more codes
| 80361 | <1% | 566 | $16K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 246 | $15K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 170 | $15K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 140 | $14K |
| 80050 | General health panel | <1% | 252 | $12K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 183 | $12K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 320 | $11K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 1,200 | $8K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 457 | $7K |
| 84484 | <1% | 774 | $6K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 262 | $6K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 380 | $5K |
| 87428 | <1% | 229 | $5K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 636 | $5K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 398 | $4K |
| 80061 | Lipid panel | <1% | 199 | $3K |
| 81001 | <1% | 1,451 | $3K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 72 | $3K |
| 83690 | <1% | 753 | $3K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 1,056 | $2K |
| 83735 | <1% | 443 | $2K | |
| 81025 | <1% | 619 | $2K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 238 | $2K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 151 | $2K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 83 | $2K |
| 85730 | <1% | 222 | $1K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 64 | $1K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 177 | $1K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 26 | $1K |
| 85610 | <1% | 293 | $1K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 12 | $974.28 |
| 81003 | <1% | 349 | $920.39 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 637 | $843.39 |
| 82550 | <1% | 203 | $762.83 | |
| 82553 | <1% | 158 | $754.02 | |
| 84439 | <1% | 69 | $675.17 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 195 | $591.04 |
| 85379 | <1% | 53 | $530.10 | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 12 | $501.68 |
| 87081 | <1% | 175 | $475.18 | |
| 73630 | <1% | 39 | $440.24 | |
| 86618 | <1% | 12 | $370.31 | |
| 73130 | <1% | 27 | $342.80 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 509 | $340.52 |
| 84145 | <1% | 17 | $314.97 | |
| 82077 | <1% | 24 | $262.01 | |
| 83880 | <1% | 12 | $253.84 | |
| 80320 | <1% | 18 | $197.26 | |
| 83605 | <1% | 24 | $176.11 | |
| 73110 | <1% | 12 | $150.35 | |
| 87186 | <1% | 14 | $122.12 | |
| 82948 | <1% | 54 | $105.78 | |
| 80076 | <1% | 15 | $101.09 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 14 | $74.96 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 291 | $65.45 |
| 85651 | <1% | 16 | $59.91 | |
| 87807 | <1% | 27 | $57.86 | |
| 87077 | <1% | 12 | $26.28 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialWEINER, JARED (CFO)
| Provider | Location | Paid |
|---|---|---|
| UPMC Presbyterian Shadyside | Pittsburgh, PA | $125.54M |
| UPMC Washington | Washington, PA | $11.22M |
| UPMC Presbyterian Shadyside | Pittsburgh, PA | $131K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.